Utilized for insomnia to manage the onset of sleep and support restful night patterns.
Mechanism of Action
Zaleplon binds selectively to the benzodiazepine Type 1 receptor on the GABA-A receptor complex. This action modulates the chloride ionophore to enhance the inhibitory neurotransmission of GABA, specifically targeting sleep initiation.
Route of Administration
Oral
Onset Time
15–20 minutes
Duration
4 hours
Contraindications
Severe hepatic impairment, Hypersensitivity to zaleplon, Severe sleep apnea
Severe Adverse Events
Complex sleep behaviors, Anaphylaxis, Amnesia — requires immediate medical attention
Common Side Effects
Drowsiness, Dizziness, Headache
Uncommon Side Effects
Nausea, Abdominal pain, Paresthesia
Drug Interactions
Alcohol, Cimetidine, Rifampin, Promethazine
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Excreted in milk; monitor infant.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Hyplon is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
